More precisely, agents that activate the cAMP/PKA/CREB pathway can lead to increased expression of Nm23-H1/2, a potential metastasis suppressor which has the ability to down-regulate metastasis formation independently of primary tumor size [64]. The gene discussed is NME1; the disease is neoplasm.